This website is intended for healthcare professionals.

FERACCRU® was effective in patients with IDA and stage 3/4 CKD without concomitant erythropoietin1,2

FERACCRU® achieved a statistically significant and clinically meaningful increase in mean Hb levels vs placebo at 16 weeks1

Study design

Mean change in Hb concentration over 52 weeks’ treatment without erythropoietin1,2

FERACCRU® achieved statistically significant improvements in ferritin, TSAT and serum iron vs placebo1

Mean change from baseline to Week 161

FERACCRU® was generally well tolerated1

Study design

Incidence of treatment-emergent AEs occurring in ≥5% of stage 3/4 CKD patients over 16 weeks’ treatment3

Adapted from Data on File – Kopyt NP, et al. AEGIS CKD oral presentation, ASN Kidney Week 2018.

AE, adverse event; CKD, chronic kidney disease; Hb, haemoglobin; IBD, inflammatory bowel disease; IDA, iron deficiency anaemia; ITT, intention to treat; SAE, serious adverse event; TSAT, transferrin saturation.

References:

  1. Kopyt NP, et al. J Am Soc Nephrol 2018;29:70–71 (abstract number FR-OR120).
  2. Pergola PE, et al. Presented at ASN 2019, poster number TH-PO451.
  3. Data on File – Kopyt NP, et al. AEGIS CKD oral presentation, ASN Kidney Week 2018.